SCHEMBL15629902

SCHEMBL15629902

CCc1cc(CC)c2cn[nH]c2c1N

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.36
METAP2 P50579 7/20 0.35
POLB P06746 1/20 0.34
HTT P42858 1/20 0.34
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
ALDH1A1 P00352 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
IDO1 P14902 1/20 0.33
TDO2 P48775 1/20 0.33
TRPA1 O75762 1/20 0.32
XDH P47989 2/20 0.32
RET P07949 1/20 0.32
PI4KA P42356 1/20 0.32
LRRK2 Q5S007 1/20 0.32
PI4K2B Q8TCG2 1/20 0.32
PI4K2A Q9BTU6 1/20 0.32
PI4KB Q9UBF8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15629838 0.90 MAPT (0.41) MAPTMETAP2POLBHTTNOS3
SCHEMBL11605466 0.88 IDO1 (0.39) MAPTMETAP2POLBHTTNOS3
SCHEMBL15629837 0.83 MAPT (0.41) MAPTMETAP2POLBHTTNOS3
SCHEMBL11608870 0.81 METAP2 (0.36) MAPTMETAP2POLBHTTNOS3
SCHEMBL11607561 0.75 IDO1 (0.37) MAPTMETAP2ALDH1A1IDO1TDO2
SCHEMBL11609591 0.74 MAPT (0.38) MAPTMETAP2HTTALDH1A1MEN1
SCHEMBL11603031 0.72 GABRP (0.35) MAPTMETAP2NOS2ALDH1A1IDO1
SCHEMBL20681042 0.71 MAPT (0.61) MAPTHTTNOS3NOS1NOS2
SCHEMBL26204751 0.71 RET (0.43) MAPTMETAP2NOS3NOS1NOS2
SCHEMBL11607563 0.70 MAPT (0.39) MAPTHTTNOS3NOS2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340521-B2 Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives GREEN CROSS CORPORATION (KR) 2016-05-17 US disclosed
US-9034921-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2015-05-19 US disclosed
US-20140274918-A1 METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES GREEN CROSS CORPORATION (KR) 2014-09-18 US disclosed
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2014-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS SLC5A2, SLC5A1, SLC2A8 MAPT 1050/4885METAP2 747/4885POLB 4650/4885
US-20140274918-A1 METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES SLC5A2, SLC5A1, SLC10A2 MAPT 1908/4885METAP2 751/4885POLB 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.